Mizutani, A.; Kobayashi, M.; Ohuchi, M.; Sasaki, K.; Muranaka, Y.; Torikai, Y.; Fukakusa, S.; Suzuki, C.; Nishii, R.; Haruta, S.;
et al. Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice. Pharmaceutics 2022, 14, 1026.
https://doi.org/10.3390/pharmaceutics14051026
AMA Style
Mizutani A, Kobayashi M, Ohuchi M, Sasaki K, Muranaka Y, Torikai Y, Fukakusa S, Suzuki C, Nishii R, Haruta S,
et al. Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice. Pharmaceutics. 2022; 14(5):1026.
https://doi.org/10.3390/pharmaceutics14051026
Chicago/Turabian Style
Mizutani, Asuka, Masato Kobayashi, Makoto Ohuchi, Keita Sasaki, Yuka Muranaka, Yusuke Torikai, Shota Fukakusa, Chie Suzuki, Ryuichi Nishii, Shunji Haruta,
and et al. 2022. "Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice" Pharmaceutics 14, no. 5: 1026.
https://doi.org/10.3390/pharmaceutics14051026
APA Style
Mizutani, A., Kobayashi, M., Ohuchi, M., Sasaki, K., Muranaka, Y., Torikai, Y., Fukakusa, S., Suzuki, C., Nishii, R., Haruta, S., Magata, Y., & Kawai, K.
(2022). Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice. Pharmaceutics, 14(5), 1026.
https://doi.org/10.3390/pharmaceutics14051026
